GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » EPS (Diluted)

GSTC (GlobeStar Therapeutics) EPS (Diluted) : $0.00 (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics EPS (Diluted)?

GlobeStar Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

GlobeStar Therapeutics's EPS (Basic) for the three months ended in Jun. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

GlobeStar Therapeutics's EPS without NRI for the three months ended in Jun. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


GlobeStar Therapeutics EPS (Diluted) Historical Data

The historical data trend for GlobeStar Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics EPS (Diluted) Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 - -0.02 - -

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, GlobeStar Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's PE Ratio falls into.



GlobeStar Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

GlobeStar Therapeutics's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.949-0)/827.325
=-0.00

GlobeStar Therapeutics's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.198-0)/1208.972
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlobeStar Therapeutics  (OTCPK:GSTC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


GlobeStar Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics Headlines

From GuruFocus

eQuine Holdings Discloses 8% Stake In AngioSoma (SOAN)

By PRNewswire PRNewswire 12-29-2018